GENETIC ANALYSIS NK -60 (F:8V8) — Stock Price
GENETIC ANALYSIS NK -60 (F:8V8) is currently trading at €0.04 EUR, up 90.43% today. Over the past 52 weeks, shares have ranged between €0.02 and €0.08. This page tracks GENETIC ANALYSIS NK -60's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 8V8 company net worth.
GENETIC ANALYSIS NK -60 (8V8) Stock Price Chart — Daily History & Trading Volume
The chart below tracks GENETIC ANALYSIS NK -60's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
GENETIC ANALYSIS NK -60 Income Statement — Revenue, Profit & Earnings by Year
GENETIC ANALYSIS NK -60's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €16.71 Million | €15.89 Million | €14.15 Million | €11.16 Million | €6.80 Million |
| Cost of Revenue | €4.70 Million | €3.11 Million | €4.43 Million | €3.91 Million | €1.28 Million |
| Gross Profit | €12.01 Million | €12.77 Million | €9.72 Million | €7.26 Million | €5.52 Million |
| Research & Development | — | — | — | — | €1.23 Million |
| SG&A | — | €2.05 Million | €2.40 Million | — | — |
| Total Operating Expenses | €27.69 Million | €30.37 Million | €37.36 Million | €39.35 Million | €35.67 Million |
| Operating Income | €-10.98 Million | €-14.48 Million | €-23.21 Million | €-28.18 Million | €-28.87 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €496.00K | €972.00K | €254.00K | €117.72K | €134.18K |
| Income Before Tax | €-11.41 Million | €-14.77 Million | €-23.82 Million | €-28.27 Million | €-29.01 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-11.41 Million | €-14.77 Million | €-23.82 Million | €-28.27 Million | €-29.01 Million |
GENETIC ANALYSIS NK -60 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes GENETIC ANALYSIS NK -60's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €52.45 Million | €42.38 Million | €53.49 Million | €64.42 Million | €83.49 Million |
| Total Current Assets | €31.07 Million | €21.70 Million | €29.06 Million | €35.44 Million | €57.60 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | €1.91 Million | €3.20 Million | €1.90 Million | €2.61 Million | €1.05 Million |
| Inventory | €804.00K | €762.00K | €1.54 Million | €1.75 Million | €2.37 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €25.37 Million | €19.88 Million | €21.49 Million | €20.28 Million | €11.40 Million |
| Total Current Liabilities | €18.97 Million | €11.84 Million | €16.05 Million | €12.95 Million | €9.97 Million |
| Long-term Debt | €3.96 Million | €4.40 Million | €300.00K | €700.00K | €1.10 Million |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €27.08 Million | €22.49 Million | €32.00 Million | €44.14 Million | €72.09 Million |
| Retained Earnings | €-26.18 Million | €-14.77 Million | €0.00 | €0.00 | €0.00 |
GENETIC ANALYSIS NK -60 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how GENETIC ANALYSIS NK -60 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €2.40 Million | €-11.62 Million | €-17.23 Million | €-19.46 Million | €-27.62 Million |
| Capital Expenditures | €5.54 Million | €1.95 Million | €643.00K | €226.74K | €1.95 Million |
| Free Cash Flow | €-3.13 Million | €-13.57 Million | €-17.88 Million | €-19.69 Million | €-29.57 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €373.00K | €134.00K | €441.00K | €324.47K | €1.22 Million |
| Depreciation | €5.17 Million | €5.24 Million | €5.58 Million | €4.83 Million | €4.53 Million |
| Change in Cash | €10.66 Million | €-2.92 Million | €-9.03 Million | €-21.49 Million | €22.62 Million |
GENETIC ANALYSIS NK -60 Earnings History — EPS Actual vs. Analyst Estimates
Track GENETIC ANALYSIS NK -60's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for GENETIC ANALYSIS NK -60.